S&P 500   4,567.02 (+0.49%)
DOW   35,756.03 (+0.22%)
QQQ   376.93 (+0.76%)
AAPL   148.57 (-0.08%)
MSFT   308.69 (-0.15%)
FB   324.55 (-0.02%)
GOOGL   2,743.61 (-0.28%)
TSLA   978.09 (+7.52%)
AMZN   3,311.86 (-0.71%)
NVDA   231.19 (+1.73%)
BABA   175.48 (-1.25%)
NIO   40.92 (+5.25%)
CGC   13.25 (-0.97%)
GE   105.66 (+1.55%)
AMD   121.65 (+1.53%)
MU   68.69 (+1.75%)
T   25.50 (+0.04%)
F   16.00 (-1.72%)
ACB   7.09 (+0.28%)
DIS   171.74 (+1.37%)
PFE   42.96 (-0.46%)
BA   212.10 (-0.41%)
AMC   37.35 (+2.05%)
S&P 500   4,567.02 (+0.49%)
DOW   35,756.03 (+0.22%)
QQQ   376.93 (+0.76%)
AAPL   148.57 (-0.08%)
MSFT   308.69 (-0.15%)
FB   324.55 (-0.02%)
GOOGL   2,743.61 (-0.28%)
TSLA   978.09 (+7.52%)
AMZN   3,311.86 (-0.71%)
NVDA   231.19 (+1.73%)
BABA   175.48 (-1.25%)
NIO   40.92 (+5.25%)
CGC   13.25 (-0.97%)
GE   105.66 (+1.55%)
AMD   121.65 (+1.53%)
MU   68.69 (+1.75%)
T   25.50 (+0.04%)
F   16.00 (-1.72%)
ACB   7.09 (+0.28%)
DIS   171.74 (+1.37%)
PFE   42.96 (-0.46%)
BA   212.10 (-0.41%)
AMC   37.35 (+2.05%)
S&P 500   4,567.02 (+0.49%)
DOW   35,756.03 (+0.22%)
QQQ   376.93 (+0.76%)
AAPL   148.57 (-0.08%)
MSFT   308.69 (-0.15%)
FB   324.55 (-0.02%)
GOOGL   2,743.61 (-0.28%)
TSLA   978.09 (+7.52%)
AMZN   3,311.86 (-0.71%)
NVDA   231.19 (+1.73%)
BABA   175.48 (-1.25%)
NIO   40.92 (+5.25%)
CGC   13.25 (-0.97%)
GE   105.66 (+1.55%)
AMD   121.65 (+1.53%)
MU   68.69 (+1.75%)
T   25.50 (+0.04%)
F   16.00 (-1.72%)
ACB   7.09 (+0.28%)
DIS   171.74 (+1.37%)
PFE   42.96 (-0.46%)
BA   212.10 (-0.41%)
AMC   37.35 (+2.05%)
S&P 500   4,567.02 (+0.49%)
DOW   35,756.03 (+0.22%)
QQQ   376.93 (+0.76%)
AAPL   148.57 (-0.08%)
MSFT   308.69 (-0.15%)
FB   324.55 (-0.02%)
GOOGL   2,743.61 (-0.28%)
TSLA   978.09 (+7.52%)
AMZN   3,311.86 (-0.71%)
NVDA   231.19 (+1.73%)
BABA   175.48 (-1.25%)
NIO   40.92 (+5.25%)
CGC   13.25 (-0.97%)
GE   105.66 (+1.55%)
AMD   121.65 (+1.53%)
MU   68.69 (+1.75%)
T   25.50 (+0.04%)
F   16.00 (-1.72%)
ACB   7.09 (+0.28%)
DIS   171.74 (+1.37%)
PFE   42.96 (-0.46%)
BA   212.10 (-0.41%)
AMC   37.35 (+2.05%)
NASDAQ:GRPH

Graphite Bio Stock Forecast, Price & News

$12.11
-0.21 (-1.70 %)
(As of 10/25/2021 11:18 AM ET)
Add
Compare
Today's Range
$12.11
$12.38
50-Day Range
$12.42
$22.47
52-Week Range
$11.72
$34.00
Volume430 shs
Average Volume383,829 shs
Market Capitalization$703.34 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GRPH News and Ratings via Email

Sign-up to receive the latest news and ratings for Graphite Bio and its competitors with MarketBeat's FREE daily newsletter.


About Graphite Bio

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GRPH
Employees
27
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$703.34 million
Next Earnings Date
11/11/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.33 out of 5 stars

Medical Sector

246th out of 1,359 stocks

Biological Products, Except Diagnostic Industry

35th out of 196 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Graphite Bio (NASDAQ:GRPH) Frequently Asked Questions

Is Graphite Bio a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Graphite Bio in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Graphite Bio stock.
View analyst ratings for Graphite Bio
or view top-rated stocks.

What stocks does MarketBeat like better than Graphite Bio?

Wall Street analysts have given Graphite Bio a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Graphite Bio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Graphite Bio?

Graphite Bio saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 3,350,000 shares, an increase of 23.2% from the September 15th total of 2,720,000 shares. Based on an average daily volume of 330,700 shares, the days-to-cover ratio is currently 10.1 days. Currently, 12.9% of the shares of the stock are sold short.
View Graphite Bio's Short Interest
.

When is Graphite Bio's next earnings date?

Graphite Bio is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Graphite Bio
.

How were Graphite Bio's earnings last quarter?

Graphite Bio, Inc. (NASDAQ:GRPH) released its quarterly earnings results on Wednesday, August, 11th. The company reported ($3.45) EPS for the quarter, missing the consensus estimate of ($0.29) by $3.16.
View Graphite Bio's earnings history
.

What price target have analysts set for GRPH?

4 equities research analysts have issued 12-month target prices for Graphite Bio's shares. Their forecasts range from $34.00 to $35.00. On average, they anticipate Graphite Bio's stock price to reach $34.67 in the next twelve months. This suggests a possible upside of 186.3% from the stock's current price.
View analysts' price targets for Graphite Bio
or view top-rated stocks among Wall Street analysts.

Who are Graphite Bio's key executives?

Graphite Bio's management team includes the following people:
  • Dr. Joshua Lehrer-Graiwer FACC, M.D., Pres, CEO & Director (Age 47, Pay $561.28k)
  • Dr. Matthew Porteus, Academic Founder & Director (Age 56, Pay $53.85k)
  • Dr. Maria Grazia Roncarolo M.D., Ph.D., Academic Founder (Age 67, Pay $53.65k)
  • Mr. Philip P. Gutry, Chief Bus. Officer, Head of Fin. & Investor Relations (Age 48, Pay $170.45k)
  • Ms. Katherine Vega Stultz, Chief Operating Officer (Age 48, Pay $335.83k)
  • Dr. Daniel Dever Ph.D., Co-founder & Head of Translational Science
  • Mr. Jerry Cacia, Chief Technical Officer (Age 54)
  • Dr. Jane Grogan Ph.D., Chief Scientific Officer (Age 54)
  • Ms. Julia Tran, Sr. VP of People

When did Graphite Bio IPO?

(GRPH) raised $224 million in an initial public offering on Friday, June 25th 2021. The company issued 14,000,000 shares at a price of $15.00-$17.00 per share.

What is Graphite Bio's stock symbol?

Graphite Bio trades on the NASDAQ under the ticker symbol "GRPH."

When does Graphite Bio's lock-up period expire?

Graphite Bio's lock-up period expires on Wednesday, December 22nd. Graphite Bio had issued 14,000,000 shares in its IPO on June 25th. The total size of the offering was $238,000,000 based on an initial share price of $17.00. After the end of Graphite Bio's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Who are Graphite Bio's major shareholders?

Graphite Bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include Strs Ohio (0.01%).
View institutional ownership trends for Graphite Bio
.

Which major investors are buying Graphite Bio stock?

GRPH stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio.
View insider buying and selling activity for Graphite Bio
or or view top insider-buying stocks.

How do I buy shares of Graphite Bio?

Shares of GRPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Graphite Bio's stock price today?

One share of GRPH stock can currently be purchased for approximately $12.11.

How much money does Graphite Bio make?

Graphite Bio has a market capitalization of $703.34 million.

How many employees does Graphite Bio have?

Graphite Bio employs 27 workers across the globe.

What is Graphite Bio's official website?

The official website for Graphite Bio is www.graphitebio.com.

How can I contact Graphite Bio?

The company can be reached via phone at 650-484-0886 or via email at [email protected].


This page was last updated on 10/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.